Sage Therapeutics (NASDAQ:SAGE) Downgraded by Wall Street Zen to Sell

Sage Therapeutics (NASDAQ:SAGE - Get Free Report) was downgraded by Wall Street Zen from a "hold" rating to a "sell" rating in a research report issued to clients and investors on Saturday.

Several other equities research analysts have also issued reports on SAGE. Canaccord Genuity Group lowered their price objective on Sage Therapeutics from $9.00 to $8.00 and set a "hold" rating for the company in a research note on Wednesday, February 12th. Needham & Company LLC reaffirmed a "hold" rating on shares of Sage Therapeutics in a research note on Friday, April 25th. HC Wainwright reaffirmed a "neutral" rating and issued a $12.00 price objective (down from $14.00) on shares of Sage Therapeutics in a research note on Wednesday, February 12th. Scotiabank reduced their price target on Sage Therapeutics from $14.00 to $12.00 and set a "sector outperform" rating on the stock in a report on Wednesday, February 12th. Finally, Wedbush reiterated a "neutral" rating and issued a $6.00 price target on shares of Sage Therapeutics in a report on Wednesday, February 12th. Two investment analysts have rated the stock with a sell rating, fourteen have given a hold rating and two have given a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $8.87.

Sage Therapeutics Stock Up 2.6%

Sage Therapeutics stock traded up $0.18 during midday trading on Friday, reaching $6.99. 876,293 shares of the stock traded hands, compared to its average volume of 1,179,035. The stock has a market cap of $437.72 million, a P/E ratio of -1.06 and a beta of 0.18. Sage Therapeutics has a 12 month low of $4.62 and a 12 month high of $13.47. The stock's fifty day moving average is $6.97 and its 200-day moving average is $6.84.

Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.99) by ($0.02). The company had revenue of $14.06 million during the quarter, compared to the consensus estimate of $14.12 million. Sage Therapeutics had a negative net margin of 971.50% and a negative return on equity of 68.18%. Sage Therapeutics's revenue for the quarter was up 78.0% on a year-over-year basis. During the same period in the previous year, the business earned ($1.80) earnings per share. On average, equities analysts predict that Sage Therapeutics will post -3.52 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. AlphaQuest LLC purchased a new position in Sage Therapeutics during the 1st quarter worth $32,000. Picton Mahoney Asset Management increased its holdings in shares of Sage Therapeutics by 126.0% in the 4th quarter. Picton Mahoney Asset Management now owns 6,423 shares of the biopharmaceutical company's stock valued at $35,000 after acquiring an additional 3,581 shares during the period. Headlands Technologies LLC purchased a new position in shares of Sage Therapeutics in the 1st quarter valued at $37,000. KLP Kapitalforvaltning AS purchased a new position in shares of Sage Therapeutics in the 4th quarter valued at $49,000. Finally, Ieq Capital LLC purchased a new position in shares of Sage Therapeutics in the 4th quarter valued at $57,000. 99.22% of the stock is currently owned by hedge funds and other institutional investors.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.